Company also commits to investing up to $100 million in German early-stage life sciences ecosystem INDIANAPOLIS – Eli Lilly and Company (NYSE: LLY) has announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company’s global parenteral (injectable) product and device manufacturing network and support an increased demand for Lilly’s …